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Background: A principle of cohort studies is that cohort membership is defined by current 
rather than future exposure information. Pharmacoepidemiologic studies using existing data-
bases are vulnerable to violation of this principle. We evaluated the impact of using data on 
future redemption of prescriptions to determine cohort membership, motivated by a published 
example seeking to emulate a “per-protocol” association between continuous versus never 
use of low-dose acetylsalicylic acid (ASA) and major bleeding (e.g., cerebral hemorrhage or 
gastrointestinal bleeding). 
Materials and methods: Danish medical registry data from 2004 to 2011 were used to 
construct two analytic cohorts. In Cohort 1, we used information about future redemption of 
low-dose ASA prescriptions to identify cohorts of continuous and never-ASA users. In Cohort 
2, we identified ASA initiators and non-initiators using only contemporaneous data and censored 
follow-up for changes in use over time. We implemented propensity score-matched Poisson 
regression to evaluate associations between ASA use and major bleeding and estimated adjusted 
incidence rate differences (IRDs) per 1,000 person-years and ratios (IRRs) overall and stratified 
by time since initiation. 
Results: Among >6 million eligible Danish adults, we identified 403,693 low-dose ASA initia-
tors (Cohort 2), of whom 189,150 were defined as continuous users (Cohort 1). Overall, IRDs 
and IRRs were similar across cohorts. However, the IRD for major bleeding in the first 90 days 
was substantially larger in Cohort 1 (IRD=25 per 1,000 person-years) compared with Cohort 2 
(IRD=10 per 1,000 person-years). 
Conclusion: Using future medication redemption data to define baseline cohorts violates basic 
epidemiologic principles. Compared with an approach using only contemporaneous data to 
define cohorts, the approach based on future redemption data generated a substantially higher 
short-term association between low-dose ASA use and major bleeding on the absolute, but not 
the relative, scale possibly due to selection and immortal time biases. 
Keywords: pharmacoepidemiology, cohort studies, immortal time bias, selection bias
Introduction
Given the limitations of randomized controlled trials for evaluating the safety of medi-
cal interventions, researchers are increasingly using routinely collected data from large 
health care databases (eg, Medicare claims, Clinical Practice Research Datalink, Scan-
dinavian medical registries, and PHARMO) to conduct such studies, as they contain 
large, diverse, and more generalizable populations.1–4 However, the valid estimation 
of the safety of medical interventions is not straightforward. The observational corol-
lary of the standard intention-to-treat approach may be inappropriate when evaluating 
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safety because of treatment changes that occur over time (ie, 
non-adherence). The resulting conservative estimate, closer 
to the null value, could attenuate or entirely mask a serious 
safety issue.5,6 An alternative analytic approach, the obser-
vational corollary of the per-protocol analysis, can address 
these concerns by explicitly evaluating the effects of drugs 
while accounting for treatment changes that occur during 
study follow-up (eg, appropriately censoring individuals 
when they stop or switch their assigned or initial treatment). 
Researchers seeking to implement per-protocol analyses 
must carefully design studies to reflect the time-varying 
nature of medication use, that is, as a daily concept (adher-
ent versus non-adherent status at a contemporaneous point 
in time) as opposed to a time-fixed concept (adherent versus 
non-adherent during the entire study period). Failure to appro-
priately characterize medication use as a daily construct can 
induce both immortal time7,8 and selection bias9,10 and invali-
date estimated treatment effects on safety outcomes. While 
these biases and design approaches to mitigate their effects 
have been well documented in the field of epidemiology, 
the increasing use of routinely collected data by researchers 
with diverse training outside of epidemiology warrants com-
munication to a wider audience. 
The primary objective of this study was to examine how 
the characterization of medication use as a time-fixed versus 
daily concept in a per-protocol analysis influences estimates 
of medical intervention effects on safety outcomes in phar-
macoepidemiologic studies using health care databases. 
To motivate our investigation, we drew upon a published 
observational study11 evaluating the association between 
low-dose acetylsalicylic acid (ASA) and the risk of major 
bleeding by restricting analysis to individuals who were 
adherent to ASA therapy (or never used ASA) during the 
follow-up period of entire study. Low-dose ASA is widely 
used and evaluation of its safety is critical, given current 
recommendations for use of ASA for primary prevention 
of cardiovascular disease and colorectal cancer.12 These 
recommendations are based on balancing the potential 
benefits of protection against cardiovascular disease and 
colorectal cancer against the adverse risk of major bleeding. 
Thus, robust and valid evaluation of ASA safety particularly 
on the absolute (risk difference) scale is needed to inform 
health care policy and practice. We used linked Danish 
nationwide data to compare two alternative approaches to 
evaluating the association between ASA and major bleeding 
risk based on characterization of ASA use as a 1) time-fixed 
(person-level) construct and 2) a daily (contemporaneously 
updated) construct. 
Materials and methods
Identification and illustration of 
“continuous” and “never”-asa users
This motivating study compared the incidence of major gas-
trointestinal and intracranial bleeding episodes (collectively, 
major bleeding) among adults aged 30–95 years old who 
initiated and continuously took ASA with those who never 
took ASA in the Puglia region of Italy from 2003 to 2008.11 
To identify the treatment comparison groups, the authors 
identified new low-dose ASA users (≤300 mg) from January 
1, 2003, to December 31, 2008. Among this group, they then 
identified current low-dose ASA users as “those who had the 
last prescription of ASA at least 75 days before hospitaliza-
tion for major bleeding events or the end of follow-up.” New 
users who did not meet the above criteria (i.e., “former” users) 
were excluded from all analyses. Individuals who did not 
receive any low-dose ASAs during the follow-up of entire 
study were considered “controls” (or never-users). 
To more clearly illustrate this study design approach, we 
generated five hypothetical individuals (A–E) eligible for 
study inclusion (Figure 1). The solid lines represent time 
when an individual had an ASA prescription (accounting 
for the time between the first and last prescription, denoted 
by circles) and the dashed lines represent unexposed time 
(not covered by an ASA prescription) from the start of a 
hypothetical database (January 1, 2004, to December 31, 
2011). The “X” denotes a major bleeding event. If the expo-
sure definitions described earlier are implemented in this 
hypothetical cohort, individuals A and E (“continuous” ASA 
user) and individual B (“never”-ASA user) will be included 
in the analysis, but individuals C and D (“former” users) 
will be excluded. 
Potential problems with this study design 
approach
The study design described can lead to a mischaracterization 
of low-dose ASA use. In general, medical interventions can 
be categorized as time-fixed or time-varying. For example, a 
surgical procedure can be considered a time-fixed interven-
tion, as the procedure is either performed or not performed 
(ie, a one-time operation). However, medications are often 
taken daily over an extended period and are, therefore, con-
sidered time-varying, as each day an individual (or his/her 
caregiver) decides to take/give the medication or not. In this 
setting, individuals may have periods of time when they take 
medicine (ie, exposed person-time) and periods when they 
do not take medicine (ie, non-exposed person-time). 
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In the motivating example, low-dose ASA use is a time-
varying exposure, but it is characterized as a time-fixed 
(person-level) exposure. In reality, “current ASA use” is 
a daily measurement that can be accurately assessed using 
contemporaneous prescription data. In an approach that 
defines “current ASA use” as a time-fixed exposure and 
excludes all individuals who do not continuously use ASA 
for the entire study period, they underestimate the potential 
person-time at risk in the ASA group (ie, by excluding “cur-
rent ASA use” among “former users”). A similar problem 
arises in the “never-user” comparison group. For example, 
an individual who starts low-dose ASA therapy later in the 
study (eg, year 2) should be able to contribute person-time 
to the non-ASA use group before beginning therapy (eg, in 
year 1). This time is truly “at risk”. Thus, a design approach 
that considers medication used as a time-fixed construct does 
not account for the true complexity and dynamic nature of 
medication use. 
Another concern is the healthy adherer/sick non-adherer 
bias, a form of selection bias, which has been well described 
in the pharmacoepidemiologic literature and can lead to 
invalid study findings.13–15 On one hand, this bias can result 
from conditioning on continued medication use, restricting 
analysis to individuals who tolerate therapy over extended 
periods of time and who may be more adherent to other 
healthy behaviors (eg, healthy diet) that are associated with 
the outcome of interest. On the other hand, conditioning on 
continued non-use of medications (ie, “never-users”) restricts 
comparisons to individuals who either 1) never have the 
indication for treatment or 2) have a contraindication for 
treatment. In principle, neither group is likely to represent a 
comparator population of interest and may have a very dif-
ferent baseline risk for bleeding events. 
Some biases cannot be avoided completely without access 
to additional information (eg, time-varying predictors of 
medication discontinuation).6 Still, use of information on 
medication use later in the study period to exclude people 
from baseline cohorts and, in turn, excluding person-time 
at risk, clearly creates the potential for bias. Together, these 
features can lead to bias in potentially opposite directions, 
making it impossible to determine the direction and magni-
tude of their combined effects. 
replication and reanalysis of the 
motivating study using Danish nationwide 
medical registries
We conducted a Danish nationwide population-based cohort 
study from January 1, 2004, to December 31, 2011, to 
replicate the motivating study. Health care in Denmark is 
provided through a national tax-funded system. Our study 
relied upon linkage between two nationwide medical regis-
tries. The first was the National Health Service Prescription 
Database (NHSPD),16 which includes data on all reimburs-
able prescriptions redeemed at community pharmacies and 
hospital-based outpatient pharmacies in Denmark since 2004. 
This database contains dispensing information including the 
Anatomical Therapeutic Chemical (ATC) Classification code, 
date of dispensing, number of prescription refills, and pack 
size. The second was the Danish National Patient Registry 
(DNPR)17 that captures information from all inpatient stays 
Figure 1 Acetylsalicylic acid (ASA) exposure and major bleeding outcome information for five hypothetical individuals eligible for Cohorts 1 and 2. The circles denote 
the first and last prescriptions and the “X”s denote the outcome events, used to define Cohort 1. The dashed lines represent unexposed person-time and the solid lines 
represent exposed person-time. 
Exposed person-time
Unexposed person-time
>75 days
>75 days
≤75 days
Individual A
Individual B
Individual C
Individual D
Individual E
Start of database: 1/1/2004 End of database: 12/31/2011
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and outpatient visits at Danish hospitals. Data recorded in the 
DNPR include the date of hospital admission and discharge, 
outpatient clinic visit date, surgical procedures, and up to 20 
discharge diagnoses. We linked NHSPD and DNPR using 
a unique 10-digit central personal registry (CPR) number 
assigned to each Danish citizen at birth and to residents 
upon immigration.
asa use
All ASA preparations are available over the counter in 
Denmark. However, low-dose ASA is generally prescribed 
by physicians, as prescriptions are 50% reimbursable via 
the national health insurance program. Low-dose ASA is 
prescribed almost exclusively for secondary prevention of 
cardiovascular disease. We used ATC code B01AC06 to 
identify this medication.
Major bleeding
Consistent with the motivating example, we identified hospi-
talizations for major bleeding, including both gastrointestinal 
bleeding and cerebral hemorrhage, based on International 
Classification of Diseases, Tenth Revision (ICD-10) codes 
(Supplementary material).
Cohort 1
To create Cohort 1, we replicated the cohort selection process 
described in the motivating study using nationwide Danish 
data for the 2004–2011 period. First, we identified all Danish 
citizens who were alive and aged 30–95 years at some point 
between 2004 and 2011. To construct continuous ASA user 
sub-cohort, we identified the date that individuals redeemed 
their first prescription for low-dose ASA (ie, the index date). 
We used a 12-month washout period, indicating no use of 
low-dose ASA. Continuous ASA users were persons whose 
last ASA prescription was ≤75 days before 1) a bleeding 
event, 2) the end of the study period (December 31, 2011), 
(3) death, or (4) emigration, whichever occurred first. This 
approach does not consider tablets dispensed or days’ supply, 
but instead assumes continuous use between the first and last 
prescription redemption. 
We then constructed the ASA never-user sub-cohort by 
assigning a random index date to all individuals during the 
study period. Among this group, we identified all individuals 
who were alive and aged 30–95 years on their assigned index 
date. Those who had filled a prescription for low-dose ASA 
at any point (before or after the index date) during the study 
period were excluded from the never-user sub-cohort. All 
individuals (continuous users and never-users of ASA) with 
a recorded diagnosis code for major bleeding in the 5 years 
prior to their index date were excluded from the analysis to 
ensure that bleeding events were incident. 
Cohort 2
We next reconstructed a cohort of low-dose ASA initiators 
and non-initiators without conditioning on use later in the 
study period. To construct ASA initiator cohort, we identified 
the date of the first ASA prescription (ie, the index date) for 
individuals aged 30–95 years. We constructed non-initiator 
cohort by first identifying a random index date for all eligible 
individuals during the study period. Among this group, we 
identified all individuals who were alive and aged 30–95 years 
at their assigned index date. However, instead of excluding 
individuals who initiated ASA later in the study period, 
we excluded only individuals from this cohort who filled a 
low-dose ASA prescription in the 12 months prior to their 
randomly assigned index date. All individuals (both ASA 
initiators and non-initiators) with a recorded diagnosis of 
major bleeding in the five years prior to the index date were 
excluded from the analysis. 
This study design allows individuals potentially to con-
tribute twice, once as a non-initiator and once as a low-dose 
ASA initiator. Figure 1 illustrates this point. Individual A 
could be selected as a non-initiator before starting low-dose 
ASA in the middle of the study period. This individual would 
stop contributing person-time on the date of low-dose ASA 
initiation. At that point, individual A would enter the study 
as a low-dose ASA initiator. 
Potential confounders
We considered the following potential baseline confounders 
measured during the five years prior to the index date: age, 
sex, previous hospitalization for alcoholism, non-bleeding 
ulcer disease, other non-bleeding conditions, and the indi-
vidual conditions included in the Charlson Comorbidity 
Index18 (using ICD-10 codes). Other potential confounders 
were measured in the year prior to the index date and included 
the use of oral anticoagulants, high-dose ASA, non-selective 
NSAIDs, glucocorticoids, selective serotonin reuptake inhibi-
tors, proton-pump inhibitors, nitrates, calcium antagonists, 
statins, and histamine-2 antagonists. All codes used to define 
these variables are listed in Supplementary material. 
Treatment changes over time
Cohort 1 explicitly conditioned on continuous ASA use and no 
use, and as such, there were no treatment changes to consider 
in the analysis. All individuals in Cohort 1 were followed from 
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their index date until 1) major bleeding event, 2) death, 3) 
emigration, or 4) end of study period (December 31, 2011), as 
implemented in the original study.11 In Cohort 2, we considered 
low-dose ASA use as a daily construct, censoring individuals 
when they changed their initial ASA use status. Continuous use 
was determined by chaining together ASA prescription redemp-
tion data using the redemption date and the defined daily dose. 
Days with overlapping prescriptions were not carried forward. 
Discontinuation of ASAs was defined as having a gap in con-
tinuous use of ASA greater than 90 days (ie, a grace period to 
allow for some delay in refills). We followed ASA initiators until 
the earliest occurrence of 1) discontinuation of ASA, 2) major 
bleeding event, 3) death, 4) emigration, or 5) end of study period 
(December 31, 2011). Similarly, we followed non-initiators from 
their index date until the earliest occurrence of 1) initiation of 
low-dose ASA, 2) major bleeding event, 3) death, 4) emigration, 
or 5) end of study period (December 31, 2011). 
statistical analysis
Characteristics of members of Cohorts 1 and 2 were reported 
using descriptive statistics. In both cohorts, we implemented a 
propensity-score matching approach to control for measured 
confounders (defined earlier) using a 8:1 greedy matching 
algorithm.19 We also included age and sex interactions with 
a history of myocardial infarction, cerebrovascular disease, 
diabetes, and concomitant use of statins, high-dose ASA, 
calcium antagonists, and nitrates. We reported matching rates 
(proportion of ASA initiators matched) for both cohorts. 
We used Poisson regression models to estimate crude and 
adjusted incidence rate differences (IRDs) per 1,000 person-
years and incidence rate ratios (IRRs) for gastrointestinal 
bleeding, cerebral hemorrhage, and composite outcome of 
major bleeding, comparing ASA users to non-users with 95% 
confidence intervals (CIs). We also reported results stratified 
by time since ASA initiation (<90 days, 90 to <180 days, 180 
days to <1 year, 1 to <2 years, and 2+ years). In Cohort 2, 
we substituted a 60- and 120-day grace period for a 90-day 
grace period to assess the robustness of our results against 
the assumption of medication continuity. 
Comparison of study results
Due to underlying differences in the source populations of 
the motivating study example and the Danish study, we could 
not directly compare findings between the two countries. 
Instead, we qualitatively compared the results from analyses 
of Cohorts 1 and 2 based on the Danish population to isolate 
the impact of different study design decisions on estimates 
of the effect of low-dose ASA use on major bleeding risk. 
All statistical analyses were performed using SAS ver-
sion 9.4 (SAS Institute, Cary, NC, USA). The study was 
approved by the Danish Data Protection Agency (record 
number 2012-41-0793). No approval from an ethics commit-
tee or informed consent from patients is required for registry 
studies in Denmark.
Results
We identified 6,360,320 Danish citizens who were alive for 
at least 1 day during 2004–2011 and eligible for inclusion in 
this study. Figure 2A illustrates the construction of Cohort 1. 
After relevant exclusions, there were 189,150 new continu-
ous users of low-dose ASA who were aged 30–95 years at 
the time they redeemed their first prescription and were free 
of major bleeding events in the previous 5 years. In total, 
2,938,044 never-users of low-dose ASA were identified after 
relevant exclusions. Figure 2B illustrates the construction 
of Cohort 2. To identify new low-dose ASA users, we used 
similar criteria as in Cohort 1 but did not require continuous 
use. This yielded 403,693 new ASA users. Non-users were 
identified using a 12-month look-back to ensure no evidence 
of low-dose ASA use; however, use of ASA later in the study 
period was not considered, resulting in a total of 3,195,091 
potential non-users. 
In both cohorts (prior to propensity-score matching), 
low-dose ASA use increased with age. In general, ASA 
use was more common among individuals with a variety of 
comorbidities and among those using concomitant medica-
tions (Tables 1 and 2). In Cohort 1, 166,983 of the 189,150 
continuous ASA users were propensity-score matched to 
never-users (match rate=88%). After matching, the distri-
bution of covariates was similar between the two groups. 
In Cohort 2, 367,326 of the 403,693 ASA users were 
propensity- score matched to non-users (match rate=91%), 
and the distribution of covariates again was similar between 
the two groups after matching. 
Cohort 1 results
Among the 189,000 continuous users and 2.9 million never-
users of low-dose ASA in Cohort 1, the median duration of 
follow-up (prior to propensity-score matching) was 3.25 
and 3.85 years, respectively. During follow-up, 6,758 major 
bleeding events (5,193 gastrointestinal bleeds and 1,565 
cerebral hemorrhages) occurred in continuous users and 
16,032 events (10,605 gastrointestinal bleeds and 5,427 cere-
bral hemorrhages) occurred in never-users. The unadjusted 
IRD, comparing continuous versus never-users of low-dose 
ASA, was 9.54 (95% confidence interval [CI]: 9.28, 9.81] per 
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1,000 person-years and the unadjusted IRR was 7.40 (95% 
CI: 7.19, 7.62; Table 3). 
After propensity-score matching, the median duration 
of follow-up was similar, at 3.24 years among the 166,983 
continuous users and 3.08 years among the 166,983 never-
users of low-dose ASA. There were 5,768 major bleeding 
events (4,410 gastrointestinal bleeds and 1,358 cerebral 
hemorrhages) among continuous low-dose ASA users and 
2,937 events (2,121 gastrointestinal bleeds and 816 cerebral 
hemorrhages) among the never-users. The adjusted IRD 
comparing continuous versus never-users of low-dose ASA 
was 5.12 (95% CI: 4.78, 5.46) per 1,000 person-years and 
the IRR was 1.92 (95% CI: 1.84, 2.01; Table 3). 
Cohort 2 results
Among the 403,693 ASA initiators and almost 3.2 million 
non-initiators in Cohort 2, the median duration of follow-up 
was 1.02 and 3.82 years, respectively. During follow-up, a 
total of 7,236 major bleeding events (5,564 gastrointestinal 
bleeds and 1,672 cerebral hemorrhages) occurred in ASA 
initiators and 19,055 events (12,520 gastrointestinal bleeds 
and 6,535 cerebral hemorrhages) occurred in non-initiators. 
Figure 2 Cohort construction for Cohort 1 (A) using future acetylsalicylic acid (asa) information and Cohort 2 (B) using contemporary asa information only.
Abbreviation: asa, acetylsalicylic acid.
Danish citizens (2004–2011): 6,360,320
Danish citizens (2004–2011): 6,360,320
Individuals with a first ASA
prescription (12-month washout):
415,865
Individuals alive at randomly
assigned index date: 5,548,889
Non-ASA users (without history of
ASA use in prior year): 5,221,402
Non-ASA user aged 30–95 years at
index date: 3,216,543
Non-ASA users (without history of
major bleeding in prior 5 years):
3,195,091
ASA users aged 30–95 years at first
script : 411,399
ASA users (without history of major
bleeding in prior 5 years): 403,693
Individuals with a first ASA
prescription (12-month washout):
415,865
Continuous ASA users: 194,972
Continuous ASA users aged 30–95
years at first script : 193,127
ASA users (without history of major
bleeding in prior 5 years): 189,150
Individuals alive at randomly
assigned index date: 5,548,889
Never-ASA users: 4,956,555
Never-ASA users aged 30–95 years
at index date: 2,954,105
Never-ASA users (without history
of major bleeding in prior 5 years):
2,938,044
A
B
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The unadjusted IRD comparing new low-dose ASA users 
versus non-users was 8.41 (95% CI: 8.18, 8.64) per 1,000 
person-years and the unadjusted IRR was 6.14 (95% CI: 
5.98, 6.31; Table 3). 
After propensity-score matching, the median duration 
of follow-up was 1.01 years among the 367,326 new low-
dose ASA initiators and 2.80 years among the 367,326 
 non-initiators, more than double compared with the 
propensity-score-matched Cohort 1. There were a total of 
6,346 major bleeding events (4,856 gastrointestinal bleeds 
and 1,490 cerebral hemorrhages) in ASA initiators and 5,370 
events (3,797 gastrointestinal bleeds and 1,573 cerebral 
hemorrhages) in non-initiators. The adjusted IRD comparing 
new users versus non-users of low-dose ASA was 4.87 (95% 
CI: 4.59, 5.14) per 1,000 person-years and the IRR was 1.99 
(95% CI: 1.92, 2.06; Table 3). Results of sensitivity analyses 
Table 1 Patient characteristics of Cohort 1 (replication cohort)
Patient characteristics Full cohort PS-matched cohort
Continuous users Never-users Continuous users Never-users
N=189,150 % N=2,938,044 % N=166,983 % N=166,983 %
age groups (years)
<50 12,745 7 1,534,688 52 11,493 7 10,204 6
50–59 31,214 17 631,015 22 27,434 16 27,126 16
60–69 56,453 30 466,101 16 50,070 30 50,261 30
70–79 49,651 26 206,731 7 43,533 26 44,255 27
≥80 39,087 21 99,509 3 34,453 21 35,137 21
gender
Female 88,974 47 1,523,641 52 80,657 48 81,436 49
Male 100,176 53 1,414,403 48 86,326 52 85,547 51
Comorbid conditions
alcoholism 3,739 2 27,062 1 3,180 2 3,389 2
non-bleeding ulcer diagnosis 1,734 1 9,202 0 1,422 1 1,514 1
non-bleeding conditions from esophagus 5,315 3 38,898 1 4,482 3 4,671 3
Diabetes 29,801 16 85,944 3 24,916 15 28,576 17
Myocardial infarction 19,920 11 3,957 0 7,440 5 3,957 2
Congestive heart failure 10,339 6 11,186 0 7,015 4 6,813 4
Peripheral vascular disease 10,640 6 11,832 0 7,772 5 7,452 5
Cerebrovascular disease 24,671 13 23,312 1 19,035 11 18,993 11
Dementia 3,896 2 7,477 0 3,308 2 3,440 2
Chronic pulmonary disease 12,902 7 59,267 2 10,483 6 10,866 7
Connective tissue disease 4,386 2 26,996 1 3,710 2 3,854 2
Ulcer disease 53 0 305 0 42 0 47 0
Mild liver disease 1,012 1 11,409 0 885 1 962 1
hemiplegia 330 0 2,315 0 279 0 301 0
Moderate to severe renal disease 3,231 2 9,492 0 2,515 2 2,477 2
any tumor 11,858 6 74,633 3 10,457 6 10,803 7
leukemia 442 0 2,433 0 388 0 371 0
lymphoma 922 1 5,241 0 790 1 835 1
Moderate to severe liver disease 218 0 2,030 0 199 0 208 0
Metastatic solid tumor 1,343 1 7,779 0 1,184 1 1,178 1
aiDs 103 0 1,957 0 81 0 74 0
Concomitant medication use
Oral anticoagulants 10,707 6 36,310 1 9,351 6 10,799 7
high-dose asa 26,246 14 18,261 1 18,191 11 16,120 10
nsaiDs 631 0 3,431 0 528 0 544 0
glucocorticoids 15,251 8 109,747 4 13,046 8 13,597 8
ssris 20,247 11 169,328 6 17,306 10 18,353 11
PPis 31,722 17 217,590 7 26,854 16 29,214 18
nitrates 14,024 7 11,813 0 9,787 6 8,723 5
Calcium antagonists 41,555 22 145,513 5 35,429 21 39,582 24
statins 56,548 30 173,160 6 47,003 28 53,147 32
h2 antagonists 3,180 2 21,316 1 2,719 2 2,785 2
Abbreviations: Ps, propensity score; asa, acetylsalicylic acid; ssris, selective serotonin reuptake inhibitors; PPis, proton-pump inhibitors; nsaiDs, nonsteroidal anti-
inflammatory drugs.
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using a 60-day and 120-day grace period in the Cohort 2 
analyses were similar (Table S1). 
Stratification by time
Figure 3A–D illustrates the IRDs per 1,000 person-years (A 
and C) and IRRs (B and D) for each outcome stratified by 
time from start of follow-up, comparing continuous users 
and never-users in Cohort 1 and new users and non-users 
in Cohort 2. As shown in the figures, the difference in IRDs 
in the first 90 days of follow-up in Cohort 1 compared with 
Cohort 2 was more than twice as high as the IRD in Cohort 
2 for both the composite and individual outcomes. This was 
likely influenced by underestimation of the time-at-risk in 
Cohort 1. However, during follow-up, the differences in IRDs 
between the two cohorts diminished. The stratified IRRs were 
more consistent in Cohorts 1 and 2 over the follow-up period.
Table 2 Patient characteristics of Cohort 2 (reconstructed cohort)
Patient characteristics Full cohort Propensity-score-matched Cohort 
Low-dose ASA 
initiators 
Non-initiators  Low-dose ASA 
initiators 
Non-initiators  
N=403,693 % N=3,195,091 % N=367,326 % N=367,326 % 
age groups (years)
<50 36,701 9 1,565,801 49 34,298 9 30,124 8 
50–59 73,674 18 683,695 21 66,717 18 65,087 18 
60–69 120,820 30 541,482 17 110,120 30 110,012 30 
70–79 101,049 25 265,918 8 91,126 25 94,192 26 
≥80 71,449 18 138,195 4 65,065 18 67,911 19 
gender
Female 191,444 47 1,646,653 52 177,264 48 178,754 49 
Male 212,249 53 1,548,438 49 190,062 52 188,572 51 
Comorbid conditions
alcoholism 7,611 2 31,268 1 6,530 2 7,015 2 
non-bleeding ulcer diagnosis 3,573 1 11,828 0 3,090 1 3,219 1 
non-bleeding conditions from esophagus 11,553 3 46,505 2 10,067 3 10,600 3 
Diabetes 57,814 14 113,453 4 49,798 14 56,664 15 
Myocardial infarction 34,253 9 9,105 0 16,776 5 9,104 3 
Congestive heart failure 18,872 5 18,054 1 14,094 4 13,448 4 
Peripheral vascular disease 20,825 5 19,997 1 15,936 4 15,129 4 
Cerebrovascular disease 48,002 12 38,802 1 37,329 10 35,886 10 
Dementia 6,184 2 9,815 0 5,323 1 5,544 2 
Chronic pulmonary disease 25,434 6 71,478 2 21,475 6 22,673 6 
Connective tissue disease 9,048 2 31,832 1 7,842 2 8,161 2 
Ulcer disease 111 0 392 0 91 0 111 0 
Mild liver disease 2,266 1 12,871 0 2,036 1 2,169 1 
hemiplegia 645 0 2,612 0 545 0 584 0 
Moderate to severe renal disease 6,192 2 12,327 0 4,998 1 4,994 1 
any tumor 23,555 6 86,392 3 21,200 6 22,482 6 
leukemia 865 0 2,893 0 769 0 797 0 
lymphoma 1,933 1 6,137 0 1,731 1 1,836 1 
Moderate to severe liver disease 457 0 2,368 0 419 0 450 0 
Metastatic solid tumor 2,499 1 8,741 0 2,233 1 2,341 1 
aiDs 233 0 2,105 0 188 0 201 0 
Concomitant medication use
Oral anticoagulants 21,500 5 50,212 2 19,213 5 21,989 6 
high-dose asa 61,067 15 47,223 2 46,312 13 43,752 12 
nsaiDs 1,273 0 4,417 0 1,127 0 1,137 0 
glucocorticoids 31,071 8 126,701 4 27,351 7 29,017 8 
ssris 39,845 10 191,574 6 34,934 10 37,814 10 
PPis 66,641 17 253,070 8 58,304 16 63,874 17 
nitrates 27,905 7 22,767 1 20,979 6 18,934 5 
Calcium antagonists 82,788 21 185,278 6 72,051 20 79,474 22 
statins 115,557 29 226,428 7 99,031 27 109,607 30 
h2 antagonists 7,090 2 26,467 1 6,215 2 6,413 2 
Abbreviations: ASA, acetylsalicylic acid; SSRIs, selective serotonin reuptake inhibitors; PPIs, proton-pump inhibitors; NSAIDs, nonsteroidal anti-inflammatory drugs.
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Figure 3 (Continued)
Time period
A
B
Major bleeding
0–89 days 24.59 (22.67, 26.51)
6.70 (5.28, 8.13)
4.70 (3.77, 5.63)
3.60 (2.92, 4.28)
2.95 (2.50, 3.39)
5.05 (4.13, 5.97)
1.28 (0.56, 2.00)
0.89 (0.41, 1.37)
0.57 (0.23, 0.90)
0.56 (0.34, 0.79)
19.54 (17.86, 21.22)
5.42 (4.19, 6.65)
3.81 (3.01, 4.60)
3.03 (2.44, 3.62)
2.38 (2.00, 2.77)
9.68 (8.73, 10.64)
4.65 (3.82, 5.49)
4.24 (3.55, 4.92)
3.93 (3.37, 4.49)
3.62 (3.20, 4.04)
1.74 (1.28, 2.20)
0.91 (0.50, 1.33)
0.88 (0.50, 1.23)
0.65 (0.37, 0.93)
0.59 (0.38, 0.81)
7.94 (7.11, 8.78)
3.74 (3.01, 4.46)
3.35 (2.76, 3.94)
3.28 (2.79, 3.76)
3.03 (2.67, 3.39)
0 5 10 15 25 30
0 5 10 15 25 30
90–179 days
180 days to 1 year
1 to <2 years
2–7 years
0–89 days
90–179 days
180 days to 1 year
1 to <2 years
2–7 years
0–89 days
90–179 days
180 days to 1 year
1 to <2 years
2–7 years
0–89 days
90–179 days
180 days to 1 year
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Cerebral hemorrhage
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IRD (95% CI)
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Time period
Major bleeding
IRD (95% CI)
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Figure 3 (A–D) Time-stratified measures of association between low-dose acetylsalicylic acid (ASA) use and major bleeding in Cohorts 1 and 2. Cohort 1 incidence rate 
differences (irDs per 1,000 person-years) and incidence rate ratios at 0–89 days, 90–179 days, 180 days to <1 year, 1 to <2 years, and 2–7 years are presented in (A) and 
(C), respectively. Cohort 2 irDs and irrs for the same time periods are presented in (B) and (D), respectively. 
Major bleeding
0–89 days 4.77 (4.15, 5.47)
2.00 (1.71, 2.34)
1.77 (1.56, 1.99)
1.62 (1.47, 1.78)
1.57 (1.47, 1.68)
3.77 (2.88, 4.92)
1.64 (1.21, 2.21)
1.47 (1.16, 1.85)
1.36 (1.12, 1.65)
1.40 (1.23, 1.59)
5.15 (4.39, 6.05)
2.14 (1.78, 2.58)
1.89 (1.64, 2.18)
1.71 (1.54, 1.92)
1.64 (1.51, 1.77)
4.68 (4.22, 5.20)
3.31 (2.95, 3.72)
2.16 (1.97, 2.36)
1.96 (1.81, 2.11)
1.63 (1.54, 1.74)
3.62 (2.95, 4.45)
2.87 (2.28, 3.62)
1.91 (1.60, 2.28)
1.59 (1.37, 1.86)
1.29 (1.15, 1.45)
5.09 (4.51, 5.75)
3.47 (3.03, 3.97)
2.25 (2.03, 2.50)
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90–179 days
180 days to 1 year
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2–7 years
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C
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Discussion
This Danish population-based study provides empirical evi-
dence of the impact of characterizing low-dose ASA use as 
a time-fixed rather than daily exposure when evaluating the 
association between low-dose ASA and major bleeding risk. 
The cohorts that relied upon information recorded later in the 
study period to define baseline study cohorts were less than 
half the size of the study cohorts that did not consider this 
information. In the overall analysis, differences between the 
IRDs per 1,000 person-years and IRRs for major bleeding 
comparing continuous versus never-users (Cohort 1) and new 
users and non-users (Cohort 2) were relatively similar. Only 
when results were stratified by follow-up time was the bias 
more apparent, particularly on the absolute scale. Both IRDs 
and IRRs varied over follow-up time, with the most elevated 
risks apparent in the early period of follow-up. However, the 
90-day IRDs in Cohort 1 were more than double the 90-day 
IRDs in Cohort 2, likely due to the underestimation of person-
time at risk in Cohort 1. 
The potential for time-related bias to impact pharma-
coepidemiologic study results and study design approaches 
that avoid these biases have been well documented in the 
literature.20–25 A recent paper by Hernan et al26 provides an 
overarching framework and general argument for how study 
design and implementation decisions can induce bias by mis-
aligning 1) timing of cohort eligibility, 2) treatment assignment 
(exposure cohort), and 3) time zero (the start of follow-up) on 
a conceptual level. The authors explain that misalignment can 
induce biases relevant to our empirical investigation, namely 
1) immortal person-time bias and 2) selection bias. 
Our study represents an empirical investigation of the 
impact of one specific scenario described by Hernan et al, 
driven by interest in studying the effects of sustained inter-
ventions on the risk of adverse outcomes. While the desire 
to create “clean” comparison groups is understandable and 
often appealing, using information on exposures later in the 
study period to assign cohort membership violates basic 
epidemiologic principles. Such an approach also is not com-
patible with emulating a hypothetical intervention, which is 
a prerequisite for causal inference (ie, individuals cannot be 
randomized to be adherent over a period of time).27–29 In our 
investigation, misalignment of study time points was intro-
duced by using information about patients’ assumed adher-
ence to low-dose ASA throughout the study period to assign 
baseline treatment strategies (exposure cohorts) and further to 
exclude individuals who were non-adherent to their assigned 
treatment strategy during follow-up. Such a study design 
approach produces immortal time bias by underestimating 
the time-at-risk among “continuous” ASA users and selection 
bias by restricting the analysis only to persons who adhere to 
their assigned treatment strategy throughout follow-up. The 
net effect of these two biases is not readily predictable and 
thus makes it difficult to interpret study findings. 
To examine the impact of this study design, we reanalyzed 
data to consider low-dose ASA use as a daily exposure and 
constructed cohorts that aligned three requisite time points: 
1) cohort eligibility, 2) treatment assignment (exposure cohort 
assignment), and 3) the start of follow-up. This eliminated 
the potential for immortal person-time bias and reduced 
the potential for selection bias. Our empirical investigation 
highlights a critically important feature of many drug-safety 
studies – namely that the risk of an adverse outcome can vary 
over time and may often peak in the early period following drug 
initiation (eg, depletion of susceptibles).21,23 Any misattribution 
of time-at-risk, particularly in these early periods, may have a 
dramatic impact on drug-outcome associations. Thus, studies 
evaluating short-term outcomes or stratifying analyses by time 
since the start of follow-up should be aware of this potential 
concern. We also observed that the magnitude of the potential 
biases may be scale-dependent, as the IRDs per 1,000 person-
years differed substantially in Cohorts 1 and 2 for the early 
time periods following drug initiation. In contrast, the IRRs 
(on a relative scale) were relatively similar across cohorts. 
A number of guidance documents provide recommenda-
tions to promote high-quality database research. Particularly 
relevant for the field of pharmacoepidemiology and compara-
tive effectiveness research are three documents endorsed by 
the International Society for Pharmacoepidemiology: 1) 
Guidelines for Good Database Selection and Use in Phar-
macoepidemiology Research,30 2) the Good ReseArch for 
Comparative Effectiveness (GRACE) principles,31 and 3) the 
recent REporting of studies Conducted using Observational 
Routinely-collected health Data (RECORD) statement (an 
addition to the STROBE guidelines).32 Yet only the GRACE 
principles include specific consideration of the potential for 
immortal time bias and none of the guidelines explicitly 
addresses concerns about alignment of the start of follow-up 
with treatment assignment and cohort eligibility. As shown 
by Suissa et al,25 Hernan et al,26 and our current investiga-
tion, the visualization of these points on a study timeline can 
be illuminating. Future revisions of these guidelines should 
consider incorporating such information. 
Strengths and Limitations
The primary strengths of this study include use of a large 
nationwide population-based cohort of Danish adults, allow-
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ing for identification of a relatively rare outcome with suf-
ficient precision. In addition, the database setting provided 
an opportunity to empirically investigate the impact of alter-
native study design approaches in a specific drug-outcome 
setting, instead of simply describing the potential for bias at 
a conceptual level.33 The generation of study findings on both 
absolute and relative scales provides additional information 
on how the bias related to study design decisions might be 
dependent on scale. 
However, our results must also be interpreted considering 
some limitations. First, our investigation was motivated by 
a study performed using an Italian database, but we did not 
have access to that data. We thus opted to reconstruct the orig-
inal study design (to the best of our ability) and then compare 
this with a daily (contemporaneous) exposure design using 
an alternative data set from a similar time period. As a result, 
we cannot make any direct comparisons with the motivating 
study. Second, while the analysis that we performed charac-
terized low-dose ASA use as a daily exposure construct, our 
results remain subject to selection bias. We did not adjust for 
factors associated with censoring (eg, via inverse probability 
weighting), given the general lack of detailed information 
about time-varying predictors of low-dose ASA adherence. 
Future work tailoring these methods for use with routinely 
collected data (eg, claims data or medical registry data) and 
their impact on bias reduction is warranted. 
Conclusion
The use of future exposure information to define baseline 
cohort membership, including drug user (and non-user) 
cohorts, can lead to bias with a generally unpredictable direc-
tion and magnitude. Depending on the specific setting, the 
impact of these design decisions on the potential for bias may 
be scale-dependent. Study design features that synchronize 
and align the start of follow-up with cohort eligibility and 
treatment assignment are required to avoid immortal time 
bias and certain forms of selection bias. 
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Supplementary materials
International Classification of Diseases, 
Tenth revision (iCD-10) and anatomical 
Therapeutic Chemical (aTC) codes used 
in analysis
Exposure
Low-dose acetylsalicylic acid (ASA) ≤300 mg (ATC code): 
B01AC06
Outcome
hospitalization for upper gastrointestinal bleeding
Bleeding from gastritis (K29.0) 
Bleeding from ulcers in the stomach (K25.0, K25.2, K25.4, 
K25.6) 
Bleeding from ulcers in the duodenum (K26.0, K26.2, K26.4, 
K26.6) 
Bleeding from gastro-duodenal ulcers (K27.0, K27.2, K27.4, 
K27.6) 
Bleeding from anastomotic ulcers, i.e. gastrojejunal ulcers 
(K28.0, K28.2, K28.4, K28.6) 
Haematemesis (K92.0)
Melaena (K92.1) 
Gastrointestinal hemorrhage without specification (K92.2)
Cerebral hemorrhage 
ICD-10 codes I60-I62
Covariates
Previous inpatient and outpatient diagnoses for:
Alcoholism (not included in Charlson) (F10, G312, G621, 
G721, I426, R780, T51, Z714, Z721)
Non-bleeding ulcer diagnosis (K25.1, K25.3, K25.5, 
K25.7, K25.9, K26.1, K26.3, K26.5, K26.7, K26.9, K27.1, 
K27.3, K27.5, K27.7, K27.9, K28.1, K28.3, K28.5, K28.7, 
K28.9)
Non-bleeding conditions from esophagitis, gastritis, duo-
denitis or Mallory–Weiss lesions (K20.9, K21, K22, K23, 
K29.1–K29.9)
Diabetes (E10-E14, O24, H360)
Modified Charlson Comorbidity Index 
(hospitalization or outpatient hospital 
visit): 
•	 Myocardial infarction, I21–I23
•	 Congestive heart failure, I50, I11.0, I13.0, I13.2
•	 Peripheral vascular disease, I70–I74, I77
•	 Dementia, F00-F03, F05.1, G30
•	 Chronic pulmonary disease, J40-J47, J60-J67, J68.4, 
J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3
•	 Connective tissue disease, M05, M06, M08, M09, M30-
M36, D86
•	 Ulcer disease, K22.1, K25-K28
•	 Mild liver disease, B18, K70.0-K70.3, K70.9, K71, K73, 
K74, K76.0
•	 Moderate to severe renal disease, I12, I13, N00-N05, 
N07, N11, N14, N17-N19, Q61
•	 Non-metastatic solid tumor, C00-C75
•	 Leukemia, C91-C95
•	 Lymphoma, C81-C85, C88, C90, C96
•	 Moderate to severe liver disease, B15.0, B16.0, B16.2, 
B19.0, K70.4, K72, K76.6, I85;
•	 Metastatic solid tumor, C76-C80
•	 AIDS, B21-B24
Co-medications (defined during the 1 
year prior to the index date)
•	 Oral anticoagulants (B01AA03, B01AA04)
•	 High dose ASA (N02BA01, N02BA51)
•	 Nonselective non-steroidal anti-inflammatory drugs 
(NSAIDs) (M01AH02, M01AH01) 
•	 Glucocorticoids (H02AB)
•	 Selective serotonin reuptake inhibitors (SSRIs) (N06AB)
•	 Proton pump inhibitors (PPIs) (A02BC05, A02BC03, 
A02BC01, A02BC02, A02BC04)
•	 Nitrates (C01D)
•	 Calcium antagonists (C08)
•	 Statins (C10AA0, B04AB0)
•	 H2 antagonists (A02BA01, A02BA03, A02BA04, 
A02BA02, A02BA07)
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Table S1 results of sensitivity analyses using a 60-day and 120-day grace period in the Cohort 2
60-day grace period
Outcome ASA 
use
No. of 
persons
No. of 
endpoint
Sum of 
person-years
Incidence rate/1, 
000 PYRs (95% CI)
Adjusted IRD 
(95% CI)
Adjusted IRR 
(95% CI)
Major bleeding no 367,326 5,370 1,093,950 4.91 (4.78, 5.04) – –
Major bleeding Yes 367,326 5,428 543,420 9.99 (9.72, 10.25) 5.08 (4.78, 5.38) 2.03 (1.96, 2.11)
Cerebral hemorrhage no 367,326 1,573 1,093,950 1.44 (1.37, 1.51) – –
Cerebral hemorrhage Yes 367,326 1,256 543,420 2.31 (2.18, 2.44) 0.87 (0.73, 1.02) 1.61 (1.49, 1.73)
gastrointestinal bleeding no 367,326 3,797 1,093,950 3.47 (3.36, 3.58) – –
gastrointestinal bleeding Yes 367,326 4,172 543,420 7.68 (7.44, 7.91) 4.21 (3.95, 4.46) 2.21 (2.12, 2.31)
120-day grace period
Outcome ASA 
use
No. of 
persons
No. of 
endpoint
Sum of 
person-years
Incidence 
rate/1,000 PYRs 
(95% CI)
Adjusted IRD 
(95% CI)
Adjusted IRR 
(95% CI)
Major bleeding no 367,326 5,370 1,093,950 4.91 (4.78, 5.04) – –
Major bleeding Yes 367,326 7,064 748,210 9.44 (9.22, 9.66) 4.53 (4.28, 4.79) 1.92 (1.86, 1.99)
Cerebral hemorrhage no 367,326 1,573 1,093,950 1.44 (1.37, 1.51) – –
Cerebral hemorrhage Yes 367,326 1,683 748,210 2.25 (2.14, 2.36) 0.81 (0.68, 0.94) 1.56 (1.46, 1.68)
gastrointestinal bleeding no 367,326 3,797 1,093,950 3.47 (3.36, 3.58) – –
gastrointestinal bleeding Yes 367,326 5,381 748,210 7.19 (7.00, 7.38) 3.72 (3.50, 3.94) 2.07 (1.99, 2.16)
Abbreviations: ASA, acetylsalicylic acid; PYRs, person-years; IRD, incidence rate difference; IRR, incidence rate ratio; 95% CI, 95% confidence interval.
